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We determined the effect of mutations generated in HIV-1 LTR on viral gene expression in six mother–infant pairs following vertical
transmission. We show that the functional domains critical for LTR function, the promoter (TATAA), enhancers (three SpI and two NFκB sites),
the modulatory region (two AP-I sites, two NFAT, one NF-IL6 site, one Ets-1, and one USF-1) and the TAR region were generally conserved
among mother–infant pairs, although we observed several patient and pair specific mutations in these important domains. We then determined the
promoter activity of our mother–infant LTR sequences by measuring CAT gene expression, which was driven by these LTRs and found that most
of these HIV-1 LTRs derived from 6 mother–infant pairs were functional. However, mutations in the important transcription factor binding sites,
including TATAA, SpI, NFκB, AP-I, NFAT, NF-IL6, Ets-1, USF-1 and TAR resulted in reduced LTR driven CAT gene expression. Taken together,
conservation of functional domains in the LTR during vertical transmission supports the notion that a functional LTR is critical in viral replication
and pathogenesis and mutations generated during the course of infection correlated with HIV-1 gene expression.
© 2008 Elsevier Inc. All rights reserved.Keywords: HIV-1 LTR; HIV-1 vertical transmission; HIV-1 gene expression; MutationsIntroduction
HIV-1 long terminal repeat, or LTR, is a cis-acting sequence
that flanks the HIV-1 genome and is necessary for proviral DNA
synthesis, integration of proviral DNA into the host genome
and transcription of the viral genes and full length genome (Al-
Harthi et al., 1998; Gaynor, 1992). The LTR can be divided into
three regions: U3, R, and U5 (Pereira et al., 2000). Within U3
there are three functional regions, the promoter (positions −78
to −1) which contains the TATAA box, the enhancer (−105 to
−79) which is comprised of two NFκB transcription factor
binding sites and three GC rich SpI sites (Gaynor, 1992), and
the modulatory region (−454 to −104) which contains two AP-I
sites, two NFAT sites, one NF-IL6 site, one USF-1 site, and one
Ets-1 site. The R (+1 to +99) region contains a unique enhancer
element termed TAR (+1 to +60), or transactivation response
element, which is important for Tat activation, efficient reverse⁎ Corresponding author. Fax: +1 520 626 2100.
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doi:10.1016/j.virol.2008.01.048transcription, and efficient packaging of viral genomic RNA
(Feng and Holland, 1988; Harrich et al., 2000; Helga-Maria
et al., 1999). While LTR diversity in infected individuals has
been examined (Blackard et al., 2000, 2001), there has been no
systematic study performed that correlates mutations generated
during vertical transmission with HIV-1 gene expression.
Vertical transmission of HIV-1 accounts for 90% of all HIV-1
infections in children and occurs at a rate of 30% (Ahmad, 2000,
2005, 2008; Pitt et al., 1997). Vertical transmission can occur at
three stages: prepartum (in utero), intrapartum (during birth), and
postpartum (breastfeeding). Several parameters have been
identified with HIV-1 vertical transmission, including advanced
clinical stage of the mother, low maternal CD4+ lymphocyte
count, high viral load, prolonged exposure of the infant to
maternal body fluids (Mayaux et al., 1995; Pitt et al., 1997;
Sperling et al., 1996), and a high viral heterogeneity in the mother
(Ahmad et al., 1995; Wolinsky et al., 1992). However, using
antiretroviral therapy (ART) during pregnancy can significantly
reduce the rate of vertical transmission (Sperling et al., 1996),
but it also selects for the transmission of ART resistant strains
(Colgrove et al., 1998). We and others have shown, by analyzing
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Mulder-Kampinga et al., 1995; Wolinsky et al., 1992) with
macrophage tropic and non-syncytium-inducing phenotypes (R5
viruses) (Matala et al., 2001; Salvatori and Scarlatti, 2001) were
transmitted from mother to infant. In addition, analysis of HIV-1
regulatory (tat and rev) and accessory (vif, vpr, vpu, and nef ) has
shown a high conservation of functional domains of these proteins
during vertical transmission (Hahn et al., 2003; Husain et al.,
2001; Ramakrishnan et al., 2005; Yedavalli and Ahmad, 2001;
Yedavalli et al., 1998a,b; 2001). We have also shown that
transmitting mothers' vif and vpr sequences were more hetero-
geneous and more functional compared with non-transmitting
mother's sequences. Furthermore, we have recently shown that
there was a low degree of genetic diversity and high conservation
of functional motifs in HIV-1 LTR in six mother–infant pairs
following vertical transmission (Mehta et al., in press). Based on
this analysis, we evaluated the functional activity of mother–
infant LTR driven CAT gene expression to measure the strength
of HIV-1 promoter as well as the effect of mutations in LTR on
HIV-1 gene expression.
We show that the functional domains in the HIV-1 LTR
sequences, including the promoter, enhancers and modulatory
regions derived from six mother–infant pairs were conserved and
correlated with efficient viral gene expression. Furthermore, we
found that mutations generated in the promoter, enhancer and/or
modulatory regions of the mother–infant LTR sequences resulted
in reduced LTR driven CAT gene expression. These results un-
derscore the importance of the functional domains of HIV-1 LTR
in viral gene expression, transmission and pathogenesis.
Results
Mutations in HIV-1 LTR in mother–infant pairs
Multiple independent (6 to 8) polymerase chain reactions
(PCRs) were performed on peripheral blood mononuclear cells
(PBMC) DNA from six mother–infant pairs, a total of 13
patients including one mother that gave birth to HIV-1 infected
twins. Eight to fifteen LTR clones, containing U3, R, and a small
portion of U5, were obtained from each patient (a total of 218
clones from all patients), cloned upstream of CAT gene and
sequenced. These LTR sequences derived from patients' PBMC
DNA represent both replicating and non-replicating viruses. The
phylogenetic analysis was done and we found a low degree of
viral heterogeneity and estimates of genetic diversity in HIV-1
LTR from six mother–infant pairs' sequences (Mehta et al., in
press). Based on the molecular characterization, we selected 10
clones from each patient and determined the promoter activity of
the LTR in the presence of HIV-1 Tat. In addition, 5 clones from
each patient were used to determine the basal activity of HIV-1
LTR driven CAT gene expression. The complete LTR sequences
of 218 clones from 6 mother–infant pairs can be retrieved from
the Genbank (accession numbers DQ848353–DQ848563). In
Fig. 1, we show only the nucleotide alignment of the impor-
tant transcription factor binding sites of selected mother–infant
HIV-1 LTR clones that exhibited mutations in these sites, as
aligned with HIV-1 NL4-3. Each mother–infant pair (B to H) islabeled alpha-numerically with clones derived from a mother
labeled with M and those derived from an infant with I.
Analysis of functional domains in mother–infant LTR sequences
HIV-1 LTR contains the promoter (TATAA), enhancers
(NFκB, Sp1) and other transcription factors binding sites (AP-I,
NFAT, NF-IL6, USF-I and Ets-1) and TAR (Gaynor, 1992).
We analyzed and compared each transcription factor binding
site of our mother–infant LTR sequences (accession numbers
DQ848353–DQ848563) with that of HIV-1 NL4-3 (Mehta et al.,
in press) and previousmutational analysis studies related toHIV-1
LTR (Gaynor, 1992; Hiebenthal-Millow et al., 2003; Naghavi
et al., 1999; Pereira et al., 2000; Reddy and Dasgupta, 1992). We
show those mother–infant LTR clones that exhibited variability
compared with HIV-1 NL4-3 in Fig. 1. In these clones, the
TATAA element that is critical for both basal and Tat-induced
LTR transcription (Berkhout and Jeang, 1992; Garcia et al., 1989)
showed a mutation from T to A at the third nucleotide in pair-G
sequences (Fig. 1), which may alter the binding site for the
TATAAbinding protein (TBP) and possibly hinderingRNAPol II
initiation of transcription (Hampsey, 1998). However, this pair
has a CATAA box starting two nucleotides upstream of wild type
TATAA box, similar to TATAA box of HIV-1 subtype E LTR
(Montano et al., 1998; van Opijnen et al., 2004), which initiates
transcription with similar efficiency (van Opijnen et al., 2004).
Our analysis of the two NFκB binding sites located within
the HIV-1 LTR (Sweet et al., 2005) showed that most LTR
sequences were conserved for the two NFκB sites (Mehta et al.,
in press). However, five infant clones from pair-B (IB2, IB5,
IB9, IB14, IB26) showed mutations in both sites; one clone
from pair-D (MD14), one clone from pair-E (ME11), one clone
from pair-G (IG2), and in pair-H three clones (MH13, IH1-1,
IH1-5) showed mutations in the second site (Fig. 1). It has been
reported that mutations of NFκB motifs in HIV-1 LTR-CAT
constructs results in marked decreases in gene expression fol-
lowing transfection into lymphoid cells with or without Tat
(Nabel and Baltimore, 1987). Several studies have also shown
that when the upstream NFκB site is mutated, gene expression
is reduced five-fold and this effect is more profound when the
first site was altered (Berkhout and Jeang, 1992; Montano et al.,
1998). We found that the first NFκB site was mostly conserved
with the exception of 5 infant clones from pair-B. We also
observed in pair-G, all mother clones and some infant clones,
contain a 27 base pair insertion 12 base pairs upstream from the
second NFκB site (full sequence can be accessed in Genbank).
Our analysis of the three SpI binding sites in HIV-1 LTR
(Gaynor, 1992) showed that our mother–infant LTR sequences
were generally conserved for the first and second sites, with a
majority of changes occurring in the third site (Mehta et al., in
press). While mutations in SpI-III site have little effect on HIV-1
gene expression (Berkhout and Jeang, 1992), mutations in all
three SpI binding sites can markedly decrease Tat-induced
activation of the LTR (Harrich et al., 1989). In pair-B, all mother
sequences had a G to A substitution in SpI-II site and four
infant-B sequences (IB2, IB5, IB9, IB26) harbored GG to
AA mutation in SpI-I site and GG to AA and G to A in SpI-II
Fig. 1. Multiple nucleotide sequence alignment of the important transcription factor binding sites and TAR in mutated HIV-1 LTR sequences from mother–infant pairs-B, C, D, E, G, and H. Complete 218 LTR sequences
from 6 mother–infant pairs can be obtained from Genbank (accession numbers DQ848353–DQ848563). The top sequence is HIV-1 NL4-3 to which all mother–infant LTR sequences are compared. Each line represents
one sequence with M referring to mothers and I referring to infants. The dots represent agreement with NL4-3 sequence, while substitutions are indicated with the corresponding nucleotide. The positions of transcription
factors binding sites are indicated above the sequence.
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173R. Mehta et al. / Virology 375 (2008) 170–181site (Fig. 1). These infant-B sequences also had a 6 base pair
insertion between SpI-II and SpI-III sites. All sequences from
pair-C showed a G to A mutation in SpI-III site and an insertion
of G one nucleotide upstream of SpI-III site, whereas some
mother's sequences harbored an additional C to T substitution in
the SpI-III site (Fig. 1). Three sequences from pair-D (ID11,
ID17, ID22) showed mutations in the first site, where only one
sequence from pair-E (IE7) showed a mutation in the second
site (Fig. 1). All sequences from pair-G showed C to T and most
of the mother's sequences T to G mutation and all pair-H
sequences showed an insertion of an A in SpI-III site.
Transcription factor binding site for AP-I has a consensus
sequence of ACTGGT for the first site and CTCAGTC for the
second site (Li et al., 1994) andwas found to be fairly conserved in
our mother–infant LTR sequences. While the first site was mostly
conserved in pairs C, D, E, G, and H (Mehta et al., in press),
mutations were generally found in the second site (Fig. 1). Single
mutation in AP-I does not affect LTR transcription as well as
substitution of T to G/C (consensus sequence) in both AP-I sites
had little effect on both basal levels and PMA activation of the
LTR (Li et al., 1994). We observed that all pair-B sequences had
mutations in the first site from AC to TG/TA. In the second site,
pairs-B,D, IH1 and IH2 showed aGT toACmutation, pair-C aGT
toCCmutation, and pair-G andMHhad aG toAmutation (Fig. 1).
In the two NFAT transcription factor binding sites, NFAT-I
and NFAT-II (Gaynor, 1992), we found that most of our mother–
infant LTR sequences were generally conserved (Mehta et al., in
press), however pair specific substitutions in both sites were also
found. Pair-B sequences showed mutations from a T to G and G
toA in the first site, A to G and CC toAT/AC in the second site as
well as three infant-B (IB2, IB5, IB9) sequences showing muta-
tions in both sites (Fig. 1). In pair-C, all sequences showed A to
G mutation in the first site, AA to GC and C to A in the second
site, all mother's sequences T to A mutation and all infant's
sequences T to G mutation in the first site (Fig. 1). Pair-D, E and
G sequences hadmutations in both sites, with a T toG andG toA
in the first site and in the second site A to G and C to A (pair-D),
TA to CG, G to A and C to A (pair-E) and A to G and CC to AT
(pair-G) (Fig. 1). In pair-H sequences, the first site showed a T to
G and an A to Gmutations, whereas C to A, A to C, and two A to
G mutations were found in the second site (Fig. 1).
NF-IL6 has a binding site in the HIV-1 LTR (Rohr et al.,
2003) and increases HIV-1 LTR driven gene expression (Akira
and Kishimoto, 1992; Buckner et al., 2002; Ruocco et al., 1996;
Tesmer and Bina, 1996). When we analyzed our mother–infant
pairs' LTR sequences, we found that the NF-IL6 binding site
was generally conserved, although some pair specific as well as
patient specific mutations were observed (Mehta et al., in press).
However, we found that pair-B sequences had A to G and T to
C, pair-D sequences A to G and G to A, most pair-E sequences
A to G and G to A, mother-G sequences T to C and GT to AC,
and infant-G and infant-H1 G to A mutations (Fig. 1).
The analysis of Ets-1 and USF-1 binding domains in our LTR
sequences were generally conserved (Mehta et al., in press).
These two proteins interact cooperatively to activate HIV-1 LTR
(Sieweke et al., 1998) and the USF-1 binding site also overlaps
with NF-IL6 by 4 base pairs (Buckner et al., 2002). Theseproteins interact via their DNA binding domains and bind
cooperatively to the USF-1 and Ets-1 binding sites in HIV-1 LTR
(Sieweke et al., 1998). We also observed some mutations in both
sites, includingG toA (infant-B and pair-G) in Ets-1 site (Fig. 1).
Moreover, we found G to A (pair-D, infant-E, pair-G, and infant-
H1) in USF-1 site (Fig. 1). Mutations in these binding domains
may affect induction of HIV-1 LTR transcription.
The TAR region is anmRNA that base pairswith itself creating
a secondary stem–loop structure which is required for processiv-
ity of transcription (Harrich et al., 1994). Within TAR there are
two important regions known as the 3-nucleotide non-base paired
bulge and a 6-nucleotide G-rich loop (Harrich et al., 1994) which
is required along with the stem for Tat transactivation (Gaynor,
1992). Tat along with host factors bind to this bulge/loop region
(Pumfery et al., 2003; Sune and Garcia-Blanco, 1995) stabilizing
the stem–loop structure and allowing transcription to continue.
Mutations in these regions will affect secondary stem–loop struc-
ture and ultimately hinder the ability of transcription factors to
bind. In general, we found that the TAR region from our mother–
infant LTR sequences were conserved, especially the bulge and
loop motifs (Mehta et al., in press). However, some mutations
were found in the loop, including GG to AA (infant-B) and T to C
(infant-G) sequences. In addition, five sequences (MB9, IB2, IB5,
IB9, IB26) showedmutations in the loop region (Fig. 1), and these
same clones showed mutations in the stem possibly altering a
correct stem–loop formation. Other mutations, including two GG
to AA (positions +2 to +3 and +53 to +54) and two G to A (+12
and +44) in four pair-B sequences, G toA (+12) andA toG (+48)
in all pair-C sequences, T to C (+14) in all infant-C sequences, A
to G (+52) in most of pair-D sequences, A to G (+49) in four
infant-E sequences and G to A (+12) and AA to GG (+48 to +49)
in all pair-H sequences were observed. These mutations may alter
correct TAR formation and HIV-1 transcription.
Characterization of biological activity of LTR from
mother–infant pairs
To evaluate the promoter and enhancer activities of our six
mother–infant LTR sequences, we selected 10 LTR clones from
each mother and infant based on molecular characterization as
described previously (Mehta et al., in press). These LTR
sequences were cloned to drive expression of a CAT reporter
gene. Since it is difficult to transfect primary T-lymphocytes
efficiently, we utilized 293 cells to transfect these LTR-CAT
clones along with Tat into 293 as these cells can provide the same
levels of transcription factors to mother and infant LTR driven
CAT constructs. We also assessed the basal levels of LTR driven
transcription from our mother–infant LTR clones (five clones
from each patient) by transfecting into 293 cells without Tat.
To ensure similar transfection efficiencies, we used a CMV-β-
galactosidase expression plasmid as a control for normalization of
transfections. We used two LTR-CAT controls: pHIV-CAT (LTR
from 3VLTR positions 8890 to 9611) and pHIV-1 NL4-3 LTR-
CAT (NL59-CAT) that contains HIV-1 NL4-3 LTR (positions
9030 to 9681, U3, R and some U5). NL59-CAT has the same
length of LTR as all mother–infant LTR clones because same
primers were used to amplify HIV-1 NL4-3 LTR. Results are
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sion. In general, we found that most of the selected mother–infant
LTR sequences were functional, with variability in HIV-1 gene
expression, and this variability correlated with mutations gen-
erated in important transcription factor binding sites in the LTR.
Fig. 2 shows LTR-CAT expression with and without Tat for
pair-B and C sequences. We found that most of the pair-B LTRs
were functional with Tat, however several clones (MB6, MB9,
MB11, IB2, IB5, IB19) had decreased levels of transcription
(Fig. 2A). When we assessed the levels of basal transcription,
we found these same clones had little or no expression in the
absence of Tat (Fig. 2B). We then examined if mutations found
in important transcription binding sites were responsible for the
decreased level of LTR-CAT expression. We found that MB6
and MB11 had mutations in SpI-II (Fig. 1) as well as upstream
of the AP-I sites (in GenBank), MB9 in SpI-II, USF-1 (Fig. 1),
TAR loop (Fig. 1) and upstream of the AP-I sites (in GenBank),
and IB19 upstream of the AP-I sites. In addition, IB2 and IB5
had four substitutions in the second AP-I site (Fig. 1), multiple
mutations between the AP-I and NFAT sties (in GenBank), one
in Ets-1, two in each NFκB site, three in SpI-II, two in SpI-I,
and several in TAR (Fig. 1). Similarly, pair-C LTR-CAT clones
showed comparable CAT expression to the wild type (NL4-3
LTR-CAT) and NL59 with Tat (Fig. 2C) and without TatFig. 2. HIV-1 gene expression in 293 cells of mother–infant LTR sequences driven
transfected in 293 cells with Tat (A) and without Tat (B) and pair-C LTRs driven C
(transfection efficiency control). Cells were lysed 48 h after transfection and CAT, β-
expressed as CAT/β-galactosidase ratios. Wild type LTR-CAT plasmids are HIV-CA
duplicate and a standard error was calculated for each transfection. Mock values ha(Fig. 2D). However, some clones showed variable levels of
CAT expression compared with wild type LTR, pHIV-CAT and
NL59, including MC1, MC2 and IC12. We found these clones
had mutations: MC1 had mutations downstream of TAR, MC2
upstream of AP-I sites, and IC12 upstream of AP-I sites, and
between AP-I and NFAT sites. These mutations are likely
altering LTR-CAT expression of these clones.
When we analyzed LTR-CATexpression in pair-D, we found
that majority of LTR clones with Tat were expressing compar-
able levels of CAT to wild type pHIV-CAT and NL59, however
MD12, MD14, MD16, ID8, ID12, ID7, ID20 had impaired
LTR function (Fig. 3A). Similarly, basal levels of transcription
of MD14, MD16, ID8, ID17, ID20 showed little to no activity
(Fig. 3B). Upon examination of the sequences, we noticed that
MD14 had a mutation in NFκB-II site (Fig. 1), upstream of AP-I
sites, between AP-I and NFAT and one in TAR, MD12 between
NFAT and NF-IL6, MD16 upstream of AP-I, ID8 upstream of
AP-I sites, between SpI-I and TATAA box, and several in U5,
ID12 upstream of AP-I, in NF-IL6 and Ets-1, ID17 upstream of
AP-I sites, in USF-1, between SpI-II and SpI-I, upstream of
TATAA, and downstream of TAR, ID20 upstream of AP-I sites,
in AP-I-II, in USF-1, in TAR and in U5, and ID22 upstream of
AP-I sites, between AP-I and NFAT, in USF-1, in SpI-I, in TAR,
downstream of TAR and in U5. In addition, these infant clonesCAT gene expression. Mother–infant pair-B LTRs driven CAT constructs were
AT constructs with Tat (C) and without Tat (D) and CMV-β-galactosidase gene
galactosidase and total protein were measured. HIV-1 gene expression values are
T (U3 and R) and NL59 (U3, R, U5). Transfections were done three times in
ve been subtracted from all transfections.
Fig. 3. HIV-1 gene expression in 293 cells of mother–infant LTR sequences driven CAT gene expression. Mother–infant pair-D LTRs driven CAT constructs were
transfected in 293 cells with Tat (A) and without Tat (B) and mother–infant pair-E LTRs driven CAT constructs with Tat (C) and without Tat (D) and CMV-β-
galactosidase gene (transfection efficiency control). Cells were lysed 48 h after transfection and CAT, β-galactosidase and total protein were measured. HIV-1 gene
expression values are expressed as CAT/β-galactosidase ratios. Wild type LTR-CAT plasmids are HIV-CAT (U3 and R) and NL59 (U3, R, U5). Transfections were
done three times in duplicate and a standard error was calculated for each transfection. Mock values have been subtracted from all transfections.
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LTRs showed comparable levels of CAT expression with Tat to
that of the controls (HIV-CAT and NL59) (Fig. 3C). However,
we observed that ME6, ME7, ME10, IE4, IE5, IE6, and IE7 had
lower levels of CAT expression compared with wild type. In
addition, basal levels of transcription of these LTRs without Tat
were non-functional, except IE1 and IE9 (Fig. 3D). Furthermore,
we found ME2 had mutations upstream of AP-I sites, between
AP-I and NFAT, between NFAT sites, in NF-IL6, in Ets-1,
between NFκB and Ets-1, between TATAA and TAR and one in
TAR, ME5 between AP-I sites, between AP-I and NFAT, in NF-
IL6 and USF-1, ME6 upstream of AP-I sites, between AP-I and
NFAT, between NFAT sites, between NFAT and NF-IL6 and
between USF-1 and Ets-1, ME10 upstream of AP-I sites, be-
tween AP-I and NFAT, and downstream of TAR, and ME11
between USF-1 and Ets-1, in NFκB-II and downstream of TAR.
In addition, the infant sequences also contained mutations,
including IE1 which had several mutations upstream of AP-I,
betweenAP-I andNFAT, in NFAT-I, betweenNFATandNF-IL6,
upstream of TATAA, in TAR and in U5, IE4 between AP-I and
NFAT, between NFAT and NF-IL6, in TAR and in U5, IE6
upstream of AP-I sites, between NFAT and NF-IL6, between
Ets-1 and NFκB-II, and in TAR, IE7 upstream of AP-I, several
between AP-I and NFAT, between NFAT and Ets-1, in Ets-1,
in SpI-II, upstream of TATAA and in TAR, and IE9 betweenAP-I and NFAT, between NFATand NF-IL6, and in TAR. These
mutations are most likely altering LTR-CAT expression in these
LTR clones.
When we analyzed transcriptional activity of pair-G clones,
we found that most clones with the exception of MG4, MG5,
MG6, IG9, IG14, and IG16 showed CAT expression with Tat
similar or higher to that of the control, HIV-CAT (Fig. 4A). The
basal transcriptional efficiency of these LTRs without Tat
showed comparable levels of activity, except MG4, MG6, IG9,
IG13, and IG16 that showed lower levels of CAT expression
(Fig. 4B). Upon closer examination of the sequences we found
MG4 had a mutation in U5, MG5 upstream of AP-I sites and
between NFAT, MG6 and IG9 between NFAT and NF-IL6 with
IG9 also having a mutation in U5, IG14 upstream of AP-I sites,
and between SpI-I and TATAA, and IG16 upstream of AP-I sites,
in NFAT-II, in TAR and in U5. All of the sequences in this pair
had a mutation in the TATAA box, TATAA to TAAAA (Fig. 1),
which is similar to the TATAA box of subtype E LTRs (Montano
et al., 1998; van Opijnen et al., 2004). Upon examination of the
sequences this pair had a CATAA box instead of a TATAA box.
It was also observed that all mother and some infant clones had
a 27 base pair insertion 11 base pairs upstream from NFκB-II
(the full sequences can be accessed in Genbank). In pair-H
sequences, the CATexpression was equal or higher to that of the
HIV-CATandNL59 controls both with (Fig. 4C) andwithout Tat
Fig. 4. HIV-1 gene expression in 293 cells of mother–infant LTR sequences driven CAT gene expression. Mother–infant pair-G LTRs driven CAT constructs were
transfected in 293 cells with Tat (A) and without Tat (B) and mother–infant pair-H LTRs driven CAT constructs with Tat (C) and without Tat (D) and CMV-β-
galactosidase gene (transfection efficiency control). Cells were lysed 48 h after transfection and CAT, β-galactosidase and total protein were measured. HIV-1 gene
expression values are expressed as CAT/β-galactosidase ratios. Wild type LTR-CAT plasmids are HIV-CAT (U3 and R) and NL59 (U3, R, U5). Transfections were
done three times in duplicate and a standard error was calculated for each transfection. Mock values have been subtracted from all transfections.
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showed higher levels of CAT as compared to the wild type.
However, we found that the basal transcriptional activity
of MH13 and IH1-1 were lower than wild type and NL59
and could be due to mutations in the NFκB-II site and between
AP-I and NFAT (MH13) and between SpI-I and TATAA (IH1-1)
(Fig. 1).
Discussion
We have recently shown that the functional domains required
for HIV-1 LTR activity were mostly conserved in six mother–
infant pairs following vertical transmission (Mehta et al., in
press). Furthermore, the biological characterization of the pro-
moter (TATAA), enhancers (three SP-I sites, two NFκB sites),
the modulatory region (two NFAT sites, two AP-I sites, one NF-
IL6 site, one Ets-1 site, and one USF-1 site) and the TAR region
revealed that these important motifs were generally conserved
and functional, although several mutations were found in these
sites that correlated with an altered LTR driven CAT gene
expression. While the majority of the 146 clones analyzed for
biological activity in this study showed a functional LTR, we
observed 36 clones that had a gene expression lower than that of
the control either with or without Tat (Figs. 2 to 4) contained
mutations in either promoter, enhancer or modulatory regions(Fig. 1). Taken together, these findings suggest that conserva-
tion of functional domains in HIV-1 LTR and correlation of
mutations generated during vertical transmission with HIV-1
gene expression is consistent with an important role of HIV-1
LTR in viral replication and pathogenesis (Freed, 2001; Garcia
et al., 1989; Gaynor, 1992; Reddy and Dasgupta, 1992).
Of the 36 clones that had decreased gene expression in our
study, 10 clones showed mutations within the enhancer region.
More specifically IB2, IB5, IB9, and MD14 all showed muta-
tions within the NFκB sites. The three IB clones had mutated
GGG sequences of NFκB to AAG in both sites and showed a
markedly reduced gene expression with and without Tat induc-
tion (Figs. 2A and 2B), as also seen with a CTC mutation
previously described (Berkhout and Jeang, 1989). Mutations
of the NFκB motifs in HIV-1 LTR-CAT constructs results in
marked decreases in gene expression following transfection
into lymphoid cells with or without Tat (Nabel and Baltimore,
1987). Several studies have also shown that when the upstream
NFκB site is mutated, gene expression is reduced five-fold and
this effect is more profound when the first site was altered
(Berkhout and Jeang, 1992; Montano et al., 1998) as we have
observed with these three IB clones. Interestingly, the majority
of clones from Pair G harbored a 27 base pair insertion 12 bases
upstream from the second NFκB site and the BLAST search
revealed no similarity to published sequences. Similar insertions
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morphisim (MFNLP), which is located just upstream of the
NFκB binding sites of variable lengths, has been described
before with little effect on transcriptional activity and replication
(Hiebenthal-Millow and Kirchhoff, 2002). However, others
studies have shown that MFNLP has a positive effect (Chen
et al., 2000; Golub et al., 1990), a negative effect (Golub et al.,
1990; Koken et al., 1992), or no effect on HIV-1 transcription
(Estable et al., 1996). Within the SpI sites we found that MB6,
MB9, MB11, IB2, IB5, IB9, IE7 and IH2-3 had mutations, and
IG9 showed a mutation downstream of SpI-I. In vitro transcrip-
tion studies of mutations in SpI binding sites have shown that
elimination of site III did not affect in vitro transcription of
the HIV-1 LTR, but mutations in sites I, II, and III resulted in
10-fold decreases in transcription in vitro (Jones et al., 1986).
While mutations in SpI-III site have little effect on HIV-1 gene
expression (Berkhout and Jeang, 1992), mutations in all three
SpI binding sites can markedly decrease Tat-induced activation
of the LTR (Harrich et al., 1989). We did not see that any of the
clones studied had mutations in all three sites. We also found
that all of pair-G sequences (Fig. 1) harbored a mutation of a
T to A at the third position of the TATAA element. Mutational
analysis of the TATAA box in yeast and human model systems
has revealed that the third position is one of the most critical
residues and must be a T (Hoopes et al., 1998; Patikoglou et al.,
1999; Wobbe and Struhl, 1990). From this it was expected
that pair-G clones should not be functional, however, these
sequences possess a CATAA box, also found in HIV-1 subtype
E LTR (Montano et al., 1998; van Opijnen et al., 2004), which
is used by approximately 12% of all cellular pol II promoters
that initiate transcription as efficiently as a TATAA box (van
Opijnen et al., 2004).
The TAR region (+1 to +60) is critical for HIV-1 Tat-induced
HIV-1 transcription and mutations within TAR can significantly
reduce LTR driven transcription. Tat along with host factors bind
to the bulge/loop region (Pumfery et al., 2003; Sune and Garcia-
Blanco, 1995) stabilizing the stem–loop structure allowing
continued transcription. Mutations in these regions will affect
secondary stem–loop structure and ultimately hinder the ability
of transcription to continue. We found that 10 clones (MB9, IB2,
IB5, IB9, IG9, IG16, MH3,MH12, IH2-3, IH2-7) had mutations
in the TAR region with almost half of them showing muta-
tions within the loop region and two clones showing mutations
downstream of TAR. It has been reported that mutations in
the hexanucleotide loop region of TAR decreases the level of
cooperative Cyclin T1 and Tat binding (Helga-Maria et al.,
1999). In addition, mutations in the TAR region may affect
secondary stem–loop structure (Das et al., 1997; Feng and
Holland, 1988) and decrease Tat and cellular factor binding
to the TAR. The three infant-B clones IB2, IB5 and IB9 had
mutations within the loop region which have been previously
reported (Garcia et al., 1989) and little to no CAT expression.
Garcia et. al, showed that the mutation of the loop region from
CTGGGA to CTAAAA drastically reduced HIV-1 LTR driven
gene expression (Garcia et al., 1989).
Of the 36 clones that had a lower gene expression than the
control, 24 sequences had mutations within the modulatoryregion. More specifically MB6, MB9, MB11, MC2, IC12,
MG5, IG14, IG16, MH3 and MH12 had mutations upstream of
the AP-I site whereas, IB2, IB5, IB9, and ID20 had mutations
within AP-I sites. It has been reported that single mutation in
AP-I does not affect LTR transcription and that a substitution of
T to G/C in both sites had little effect on basal levels as well as
PMA activation of the LTR (Li et al., 1994). From our mother–
infant sequences we also observed IC12 had mutations between
AP-I and NFAT sites, but IB2, IB5, IB9, ID12, ME6, ME7, IE5
and IE7 had mutations within the NFAT sites whereas ME2,
MG9 and IG9 had mutations downstream of the NFAT sites.
Only one clone, ID12 had a mutation within the NF-IL6 site. It
has been shown that NF-IL6 can bind to and increase HIV-1
LTR driven gene expression (Akira and Kishimoto, 1992;
Buckner et al., 2002; Ruocco et al., 1996; Tesmer and Bina,
1996), therefore mutations in this site may alter LTR gene
expression. USF-1 and Ets-1 interact cooperatively to increase
HIV-1 gene expression (Sieweke et al., 1998) and we saw that 5
clones (MB9, ID8, ID17, ID20, and ME5) had mutations within
USF-1 and 6 clones (IB2, IB5, IB9, ID12, IE7, and ME2) had
mutations within Ets-1.
The 5VLTR does not encode proteins capable of interacting
with the immune system. However, Nef overlaps a region of the
3V LTR and immune pressure exerted on these regulatory
proteins may indirectly influence LTR diversity (Blackard et al.,
2000). It is also known that the LTR is responsive to cytokines,
transcriptional activators, as well as viral proteins. Nucleotide
changes within regions responsible for binding these regulators
may affect transcriptional fitness. One study has demonstrated
that a single point mutation in the LTR abolished responsiveness
to one cellular protein while simultaneously increasing respon-
siveness to another (Verhoef et al., 1999). These observations
suggest that HIV-1 gene regulation by the LTR maybe be linked
to transmission (Al-Harthi et al., 1999, 1998; Hashemi et al.,
1999; Montano et al., 1997). Those LTRs that respond better to
host factors will likely be activated at higher levels than those
that do not respond, resulting in higher viral gene expression,
and ultimately influencing transmission. Better understanding of
the mechanisms of vertical transmission needs to be accom-
plished. Previously, we have characterized many of the viral
genes associated with vertical transmission (Hahn et al., 1999,
2003; Husain et al., 2001; Matala et al., 2001; Ramakrishnan
et al., 2005; Sundaravaradan et al., 2005;Wellensiek et al., 2006;
Yedavalli and Ahmad, 2001; Yedavalli et al., 1998a,b; 2001),
which has allowed researchers to gain a better understanding of
molecular mechanisms of vertical transmission. The data pre-
sented in this study emphasizes the importance of LTR in viral
gene regulation and pathogenesis.
Materials and methods
Patient population and sample collection
This study was approved by the Human Subjects Committee
of the University of Arizona, Tucson, Arizona and the Institu-
tional Review Board of the Children's Hospital Medical Center,
Cincinnati, Ohio. Written informed consent was obtained from
178 R. Mehta et al. / Virology 375 (2008) 170–181patients participating in this study. Blood samples were col-
lected from mother–infant pairs; the infants' ages at the time
of specimen collection were 4.75 months (infant-B), 14 months
(infant-C), 28months (infant-D), 34months (infant-E) 24months
(infant-G) and 7 months (infant twins-H). The demographic,
clinical and laboratory findings for the HIV-1-infected mother–
infant pairs are shown in Table 1. Each mother–infant pair is
labeled alpha-numerically with clones derived from the mother
labeled with M and those derived from the infant with I.
Isolation of DNA from peripheral blood mononuclear cells
The peripheral blood mononuclear cells (PBMCs) were iso-
lated by a single-step Ficoll-Paque procedure (Pharmacia-LKB,
Piscataway, NJ) from the whole blood of HIV-1-positive mothers
and their infants. DNA was isolated according to a modified
procedure as described previously (Ahmad et al., 1995). Approxi-
mately 106 PBMCs were centrifuged at 12,000 rpm for 2 min and
the cell pellet was resuspended in 0.5 ml of TNE buffer (0.5 M
Tris–HCl [pH 7.5], 0.1 M NaCl, 1 mM EDTA). The suspension
was treated with 0.5% sodium dodecyl sulfate (SDS) and pro-
teinase K (10 μg/ml; Boehringer Mannheim, Indianapolis, IN) at
60 °C for 3 h, followed by several extractions with phenol and
chloroform. The DNA was precipitated with ethanol and dis-
solved in 50–100 μl of TE buffer (10 mM Tris–HCl [pH 7.5],
1 mM EDTA).
Polymerase chain reaction amplification
A two-step polymerase chain reaction (PCR) amplification,
first with outer primers and then with nested or inner primers, was
performed to detect the presence of HIV-1 in infected patients
PBMCs (Ahmad et al., 1995). An equal amount of HIV-1
PBMC DNA (approximately 25–50 copies, minimum) was used
from each patient as determined by end-point dilution. DNATable 1
Demographic, clinical and laboratory parameters of HIV-1 infected mother–infant p
Patient Age Sex Race a CD4+ cells/mm3 Length of infect
Mothers
B 28 years B 509 11 months
C 23 years W 818 1 year 6 months
D 31 years W 480 2 year 6 months
E 26 years B 395 2 years
G 23 years W 480
H 33 years B 538 5 months
Infants
B 4.75 months M B 1,942 4.75 months
C 14 months F W 772 14 months
D 28 months M W 46 28 months
E 34 months M B 588 34 months
G 24 months F W 4,379 24 months
H1 7 months F B 3,157 7 months
H2 7 months F B 2,176 7 months
a Race: B-African American W-Caucasian.
b The closest time of infection that we could document was the first positive HI
Therefore, these dates may not reflect the exact dates of infection.
c Evaluation for infants is based on CDC criteria.
d ddC, zalcitabine.oligonucleotide outer primers LTR1 (5V CTCAGGTACCTT-
TAAGACCAATGACT, sense) and LTR2 (5VTAGAGATTTTC-
CACACTGACTAAAA antisense) and inner primers LTR3
(5V GGGGACAAGTTTGTACAAAAAAGCAGGCTAAGGC-
AGCTGTAGATCTTAGCCACT, sense) and LTR4 (5VGGGGA-
CCACTTTGTACAAGAAAGCTGGGTCTGAGGGATCTCTA
GTTACCAGAGT, antisense) were designed according to pub-
lished HIV-1 sequences of NL4-3. The PCRs were performed
according to the procedure of Ahmad et al. (Ahmad et al., 1993) in
25 μl reaction mixtures, each containing 2.5 μl of 10× PCR buffer
(100 mM Tris–HCl [pH 8.3], 100 mM KCl, 0.02% Tween 20),
2.5 mM MgCl2, 400 μM each of dATP, dCTP, dGTP, and dTTP,
0.2 to 1.0 μM each of outer primers and 2.5 U of TaKaRa LA Taq
polymerase enzyme (TaKaRa Biomedicals, Shiga, Japan). The
reactions were carried out for 35 cycles, each cycle consisting of
94 °C for 30 s, 45 °C for 45 s, and 72 °C for 3 min. After the first
round of PCR, 5 μl of the product was amplified using the
corresponding inner primers for 35 cycles using the same param-
eters. The PCR products were analyzed by electrophoresis on a
1.2% agarose gel.
Construction of an HIV-1 LTR driven CAT gene expression
vector
To determine the biological relevance of HIV-1 LTR, we
constructed a CAT gene expression vector, which is under the
control of HIV-1 LTR cloned from six mother–infant pairs
following vertical transmission. To do this, we enzymatically
digested CMV-CAT plasmid with HindIII and XbaI in a total
volume of 50 μl to remove the CMV promoter such that the CAT
gene is left behind. We then made blunt ends, which were
dephosphorylated using shrimp alkaline phosphate [SAP (USB)]
to prevent the ends from rejoining. This promoterless vector was
then used in a ligation reaction with 10–20 ng of GATEWAY
Cloning System Reading Frame Cassette C (Invitrogen), and 1 Uairs
ion b Antiviral drug Clinical evaluation c
None Asymptomatic
None Asymptomatic
None Asymptomatic
ZDV Symptomatic AIDS
None Asymptomatic
None Asymptomatic
None Asymptomatic, P1A
ZDV Symptomatic AIDS, P2A, D1, 3, F
ddCd Symptomatic AIDS, P2A, B, F; failed ZDV therapy
ZDV Symptomatic AIDS, P2A
ZDV Asymptomatic, P1B
ACTG152 Hepatosplenomegaly, lymphadenopathy
ACTG152 Hepatosplenomegaly, lymphadenopathy
V-1 serology date or the first visit of the patient to the AIDS treatment center.
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One microliter of the ligation was transformed into DB3.1
Competent Cells as these cells are not killed by the ccdB gene,
which is lethal to any other strain. DNAwas isolated from these
transformed cells and restriction digests were performed using
many different enzymes to ensure the GATEWAY Cloning
System Reading Frame Cassette C was inserted in the correct
orientation. This is the Destination Vector (DestVC) that was used
in the second step of the GATEWAY cloning system (Invitrogen).
Cloning and DNA sequencing
The PCR products amplified by inner primer pair LTR3/
LTR4, which contains U3, R and some U5 regions, were cloned
into the GATEWAY cloning system, using DestVC, upstream
of CAT gene. Individual bacterial colonies were screened for
the presence of recombinants by restriction enzyme analysis
of plasmid DNA. The clones with correct sized inserts were
selected for large scale DNA preparation, followed by manual
sequencing of 8 to 15 clones for each patient. Sequencing was
performed using either Sequenase version 2, Thermosequenase
cycle sequencing protocol (U.S. Biochemical, Cleveland, Ohio)
or ABI PRISM® 3700 DNA automated sequencing system at
the University of Arizona Biotechnology center.
Cell lines and DNA transfections
293 cells were cultured in MEM supplemented with 10%
FBS (Invitrogen) and 1× penicillin/streptomycin and split as
cells reached 75% confluency. Once cells were trypsinized and
washed, 293 cells were plated in 6 well plates at 180,000 cells/
well 12–18 h before transfection was performed. On day of
transfection, 1.4 μg of LTR-CAT constructs, 0.4 μg Tat DNA,
and 0.15 μg of CMV-β-galactosidase (transfection efficiency
control DNA)were cotransfected using a lipid based transfection
method, Trans-It 293 (Mirus). Briefly, for every microgram of
DNA, 2 μl of lipid was used. Lipid was added to 200 μl of Opti-
MEM (Invitrogen) and allowed to incubate for 20 min at room
temperature. After 20 min, the lipid–Opti-MEM mixture was
added dropwise to the DNA. This was then allowed to incubate
for 30 min at room temperature. After incubation, fresh media
was added to plated cells and 200 μl of lipid–Opti-MEM–DNA
mixture was added dropwise to cells. Cells were then lysed with
1× Reporter Lysis Buffer 48 h post-transfection. Lysates were
either used for enzymatic assays or frozen and stored at −80 °C
for future use.
CAT, β-galactosidase and protein assays
Lysates from transfected 293 cells were then assayed for
levels of CAT, β-galactosidase and total cellular protein. CAT
was assayed using a CAT-ELISA kit (Roche) per manufac-
turer's instructions. Briefly, 200 μl of cell lysate was added to
the well and allowed to incubate at 37 °C for 1 h. The wells were
then washed, and an Anti-CAT-DIG antibody was added and
incubated for 1 h at 37 °C. This was then washed and Anti-DIG-
POD was added for another hour at 37 °C. After washing, PODsubstrate was added and allowed to incubate for 15–30 min at
room temperature. After color development the absorbance was
measured at 480 nm. β-galactosidase levels were determined
using a β-Galactosidase Enzyme Assay System with Reporter
Lysis Buffer (RLB) (Promega). Briefly, 20 μl of cell lysate was
placed into a 96-well plate along with 20 μl of 2× Assay Buffer
(200 mM sodium phosphate buffer [pH 7.3], 2 mM MgCl2,
100 mM β-mercaptoethanol, and 1.33 mg/ml o-nitrophenol
galactopyranoside [ONPG]) and allowed to incubate at 37 °C
for 30 min. Absorbance was read immediately at 418 nm in a
plate reader. Total cellular protein was assayed using the Protein
Assay ESL kit (Roche). Briefly, 20 μl of lysate was pipetted into
a 96-well plate. Reagent A was then added (20 μl) and allowed
to incubate for 10–15 min at room temperature. Following
incubation, 200 μl of Reagent B was then added, and the plate
was read immediately at 480 m. Appropriate controls were per-
formed for each assay done.
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